MX2019015246A - Oligonucleotidos antisentido de tirosinasa. - Google Patents

Oligonucleotidos antisentido de tirosinasa.

Info

Publication number
MX2019015246A
MX2019015246A MX2019015246A MX2019015246A MX2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A
Authority
MX
Mexico
Prior art keywords
tyrosinase
human tyrosinase
antisense oligonucleotides
nucleic acid
mrna
Prior art date
Application number
MX2019015246A
Other languages
English (en)
Inventor
Soyoung Kim
Daram Jung
Hye Mi Park
Seon-Young Han
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Priority claimed from PCT/KR2018/008143 external-priority patent/WO2019022434A1/en
Publication of MX2019015246A publication Critical patent/MX2019015246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

Se proporcionan derivados de ácido nucleico peptídico con especificidad de objetivo contra un sitio de empalme 3' del pre-ARNm de tirosinasa humana. Los derivados de ácido nucleico peptídico inducen potencialmente una variante de empalme del ARNm de tirosinasa humana en células y son útiles para tratar de forma segura indicaciones o afecciones dermatológicas que implican la proteína tirosinasa humana tras la administración tópica.
MX2019015246A 2017-07-24 2018-07-19 Oligonucleotidos antisentido de tirosinasa. MX2019015246A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170093605 2017-07-24
KR1020170167558A KR20190011181A (ko) 2017-07-24 2017-12-07 티로시나아제 안티센스 올리고뉴클레오티드
PCT/KR2018/008143 WO2019022434A1 (en) 2017-07-24 2018-07-19 ANTISENSE OLIGONUCLEOTIDES OF TYROSINASE

Publications (1)

Publication Number Publication Date
MX2019015246A true MX2019015246A (es) 2020-07-20

Family

ID=65367910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015246A MX2019015246A (es) 2017-07-24 2018-07-19 Oligonucleotidos antisentido de tirosinasa.

Country Status (13)

Country Link
US (1) US20230148418A1 (es)
EP (1) EP3658570B1 (es)
JP (1) JP7109532B2 (es)
KR (1) KR20190011181A (es)
CN (1) CN110831958B (es)
AR (1) AR112761A1 (es)
AU (1) AU2018308224B9 (es)
BR (1) BR112020000461A2 (es)
CA (1) CA3069570A1 (es)
ES (1) ES2906396T3 (es)
MX (1) MX2019015246A (es)
SG (1) SG11201912447RA (es)
TW (1) TWI782999B (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US20040215006A1 (en) * 2003-04-25 2004-10-28 Isis Pharmaceuticals Inc. Modulation of tyrosinase expression
US20050215506A1 (en) * 2001-12-20 2005-09-29 Bennett C F Modulation of tyrosinase expression
AR039007A1 (es) * 2002-03-19 2005-02-02 Monsanto Technology Llc Acidos nucleicos y polipeptidos de homogentisato prenil transferasa (hpt) y usos de los mismos
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
KR100569773B1 (ko) * 2003-12-22 2006-04-10 한국전자통신연구원 이동통신 시스템의 프레임 구성 장치 및 프레임 구성 방법
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
FR2890074B1 (fr) * 2005-09-01 2007-11-23 Lvmh Rech Nouveaux oligonucleotides anti-genes specifiques de la tyrosinase comme agents depigmentants
FR2909383B1 (fr) * 2006-12-05 2009-04-17 L V M H Rech Groupement D Inte Nouveaux oligonucleotides et utilisation d'oligonucleotides interagissant avec le gene codant pour la tyrosinase related protein-1 (trp-1) pour en moduler son expression comme agents depigmentants.
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
US20190337987A1 (en) * 2016-12-30 2019-11-07 Olipass Corporation Exon skipping by peptide nucleic acid derivatives

Also Published As

Publication number Publication date
TW201907958A (zh) 2019-03-01
CN110831958A (zh) 2020-02-21
ES2906396T3 (es) 2022-04-18
AU2018308224B9 (en) 2022-03-31
BR112020000461A2 (pt) 2020-07-21
TWI782999B (zh) 2022-11-11
SG11201912447RA (en) 2020-02-27
AU2018308224A1 (en) 2020-02-06
CN110831958B (zh) 2023-07-04
AU2018308224B2 (en) 2022-03-24
KR20190011181A (ko) 2019-02-01
EP3658570B1 (en) 2021-12-01
JP7109532B2 (ja) 2022-07-29
US20230148418A1 (en) 2023-05-11
EP3658570A1 (en) 2020-06-03
AR112761A1 (es) 2019-12-11
RU2019142512A (ru) 2021-08-24
CA3069570A1 (en) 2019-01-31
EP3658570A4 (en) 2021-04-14
RU2019142512A3 (es) 2021-11-08
JP2020528899A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
EP4349414A3 (en) Methods and formulations for transdermal administration
WO2013059737A3 (en) Tissue treatment device and related methods
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
EP3684353A4 (en) TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
BR112019002387A2 (pt) oligonucleotídeos antissenso de receptor de andrógeno
EP4166667A3 (en) Compositions for modulating c9orf72 expression
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
MX2019008445A (es) Calmante de dolor scn9a antisentido.
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
NZ702967A (en) Diclofenac formulations
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EA200970154A1 (ru) Косметические или дерматологические препараты, содержащие n-ацетилцистеин
EP3818991A3 (en) Compositions and methods for treating diseases
EA201891235A1 (ru) Составы лекарственных средств для лечения злокачественной опухоли
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
WO2014153385A3 (en) Methods of treating metabolic disorders
BR112018012749A2 (pt) composições para higiene pessoal
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2011124245A3 (de) Mikrobiologisch stabile anwendungsfreundliche zubereitungen mit anionischen oder kationischen wirkstoffen
MX2019007903A (es) Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25).
WO2016205397A3 (en) Target-specific delivery of therapeutic agents